Rubin Ethel 4

What Happened

• Director Ethel Rubin was granted 178,000 restricted stock units (RSUs) on February 26, 2026. The grant was reported as an award (code A) with an acquisition price of $0.00 (RSUs awarded in lieu of cash).
• These RSUs are not immediately tradable shares; they represent the right to receive common stock if/when the RSUs are earned and subsequently vested and settled.

Key Details

• Transaction date: 2026-02-26; Filing/accession date: 2026-02-27 (reported promptly).
• Amount: 178,000 RSUs; reported acquisition price: $0.00 (grant in lieu of cash).
• Vesting/earning schedule (footnote): RSUs are earned in 12 approximately equal monthly installments beginning Feb 1, 2026. Once earned, they remain subject to additional time-based vesting in a single installment on Feb 26, 2027, and require continued service to the company.
• Shares owned after transaction: not specified in the provided filing.
• No 10b5-1 plan, tax withholding, or late filing noted in the filing information provided.

Context

• RSU awards are a form of compensation, not an out-of-pocket purchase or sale. The reported $0.00 reflects that Rubin did not pay cash to receive the RSUs; economic value depends on VolitionRx’s future share price when/if RSUs vest and are settled.
• Such grants are common for board compensation and do not, by themselves, indicate a buy or sell signal.